Table 1 This table depicts the number of cases of MRONJ reported to the FAERS database for each of the twenty most commonly reported medications from 2010 to 2014 and from 2015 to 2021
2010 to 2014 | 2015 to 2021 | ||||||
|---|---|---|---|---|---|---|---|
Medication (Drug Class): | Drug Indication: | # of ONJ Cases | % of total reported | Medication: | Drug Indication: | # of ONJ Cases | % of total reported |
1. Zoledronic Acid (BP) | Osteoporosis | 1903 | 60.8 | 1. Denosumab (RANKL-i) | Osteoporosis | 3148 | 54.5 |
2. Alendronate (BP) | Osteoporosis | 576 | 18.4 | 2. Zoledronic Acid (BP) | Osteoporosis | 2027 | 35.1 |
3. Denosumab (RANKL-i) | Osteoporosis | 506 | 16.2 | 3. Alendronate (BP) | Osteoporosis | 447 | 7.7 |
4. Pamidronate (BP) | Osteoporosis | 301 | 9.6 | 4. Ibandronate (BP) | Osteoporosis | 200 | 3.5 |
5. Ibandronate (BP) | Osteoporosis | 112 | 3.6 | 5. Lenalidomide (immunomodulator w multiple MOA) | Cancer; immunomodulator with multiple MOA | 150 | 2.6 |
6. Lenalidomide (immunomodulator w multiple MOA) | Cancer; immunomodulator with multiple MOA | 82 | 2.6 | 6. Pamidronate (BP) | Osteoporosis | 115 | 2.0 |
7. Risedronate (BP) | Osteoporosis | 81 | 2.6 | 7. Bevacizumab (anti-VEGF) | Cancer; monoclonal anti-VEGF | 114 | 2.0 |
8. Sunitinib (TKI, antiangiogenic) | Cancer; tyrosine kinase inhibitor | 56 | 1.8 | 8. Prednisolone (CS) | Variety of different indications; many different MOA | 103 | 1.8 |
9. Bevacizumab (anti-VEGF) | Cancer; monoclonal anti-VEGF | 50 | 1.6 | 9. Risedronate (BP) | Osteoporosis | 101 | 1.7 |
10. Prednisolone (CS) | Variety of different indications; many different MOA | 42 | 1.3 | 10. Dexamethasone (CS) | Variety of different indications; many different MOA | 99 | 1.7 |
11. Dexamethasone (CS) | Variety of different indications; many different MOA | 35 | 11.1 | 11. Everolimus (mTOR i) | Cancer; immunomodulator | 90 | 1.6 |
12. Docetaxel (MT depolymerizer) | Cancer; MT depolymerization | 24 | 0.8 | 12. Sunitinib (TKI, antiangiogenesis) | Cancer; tyrosine kinase inhibitor | 78 | 1.4 |
13. Letrozole (aromatase inhibitor) | Cancer; hormonal effects | 15 | 0.5 | 13. Palbociclib (CDK 4/6 inhibitor) | Cancer; hormonal effects | 74 | 1.3 |
14. Methotrexate (antimetabolite) | Cancer; cytotoxic agent | 15 | 0.5 | 14. Docetaxel (MT depolymerizer) | Cancer; MT depolymerization | 54 | 0.9 |
15. Everolimus (mTOR inhibitor) | Cancer; immunomodulator | 12 | 0.4 | 15. Methotrexate (antimetabolite) | Cancer; cytotoxic agent | 51 | 0.9 |
16. Paclitaxel (MT depolymerizer) | Cancer; MT depolymerization | 9 | 0.3 | 16. Prednisone (CS) | Variety of different indications; many different MOA | 47 | 0.8 |
17. Imatinib (TKI) | Cancer; tyrosine kinase inhibitor | 8 | 0.3 | 17. Pomalidomide (unclear; multiple MOA | Cancer; immunomodulator | 29 | 0.5 |
18. Sorafenib (TKI, anti VEGF) | Cancer; immunomodulator | 8 | 0.3 | 18. Radium 223 (emits high energy particles inducing cytotoxic DNA ds breaks in cells) | Cancer; radiotherapy | 25 | 0.4 |
19. Teriparatide (rPTH) | Osteoporosis; hormonal effects | 7 | 0.2 | 19. Nivolumab (PD Rc-1 inhibitor) | Cancer; immunomodulator | 23 | 0.4 |
20. Temsirolimus (mTOR inhibitor) | Cancer; immunomodulator | 6 | 0.2 | 20. Cabozantinib (TKI) | Cancer; tyrosine kinase inhibitor | 22 | 0.4 |